|
US135A
(en)
|
|
1837-03-03 |
|
Jesse j |
|
US7812A
(en)
|
|
1850-12-03 |
|
Nail-plate feeder and turner |
|
CA209066A
(en)
|
|
1921-03-01 |
Tschirner Frederick |
Conversion of potassium to soluble state
|
|
US6355476B1
(en)
|
1988-11-07 |
2002-03-12 |
Advanced Research And Technologyinc |
Nucleic acid encoding MIP-1α Lymphokine
|
|
US6303121B1
(en)
|
1992-07-30 |
2001-10-16 |
Advanced Research And Technology |
Method of using human receptor protein 4-1BB
|
|
US6362325B1
(en)
|
1988-11-07 |
2002-03-26 |
Advanced Research And Technology Institute, Inc. |
Murine 4-1BB gene
|
|
DE122004000008I1
(de)
|
1991-06-14 |
2005-06-09 |
Genentech Inc |
Humanisierter Heregulin Antikörper.
|
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
|
WO1995001782A2
(en)
|
1993-07-09 |
1995-01-19 |
R.P. Scherer Corporation |
Method for making freeze dried drug dosage forms
|
|
US5457895A
(en)
|
1993-10-01 |
1995-10-17 |
R. P. Scherer Corporation |
Method of identifying freeze-dried dosage forms
|
|
US5837287A
(en)
|
1994-10-28 |
1998-11-17 |
R P Scherer Corporation |
Process for preparing solid pharmaceutical dosage forms
|
|
US6051227A
(en)
|
1995-07-25 |
2000-04-18 |
The Regents Of The University Of California, Office Of Technology Transfer |
Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
|
|
US7423125B2
(en)
|
1995-08-01 |
2008-09-09 |
Vegenics Limited |
Antibodies to VEGF-C
|
|
US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
|
IL129138A0
(en)
|
1996-10-11 |
2000-02-17 |
Bristol Myers Squibb Co |
Methods and compositions for immunomodulation
|
|
WO1998036738A1
(en)
|
1997-02-20 |
1998-08-27 |
Therics, Inc. |
Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
|
|
DK1325932T5
(da)
|
1997-04-07 |
2005-10-03 |
Genentech Inc |
Anti-VEGF antistoffer
|
|
US20020032315A1
(en)
|
1997-08-06 |
2002-03-14 |
Manuel Baca |
Anti-vegf antibodies
|
|
EP1001748B1
(en)
|
1997-07-25 |
2006-04-19 |
Alpex Pharma S.A. |
A process for the preparation of a granulate suitable to the preparation of rapidly disintegrable mouth-soluble tablets
|
|
RU2233654C2
(ru)
|
1998-11-20 |
2004-08-10 |
Ртп Фарма Инк. |
Диспергируемые стабилизированные фосфолипидом микрочастицы
|
|
EE05627B1
(et)
|
1998-12-23 |
2013-02-15 |
Pfizer Inc. |
CTLA-4 vastased inimese monoklonaalsed antikehad
|
|
HU230586B1
(hu)
|
1999-06-25 |
2017-02-28 |
Genentech, Inc. |
Anti-ErbB antitest/maytansinoid konjugátumok alkalmazása rákos betegségek kezelésére szolgáló gyógyszer előállítására
|
|
US6284270B1
(en)
|
1999-08-04 |
2001-09-04 |
Drugtech Corporation |
Means for creating a mass having structural integrity
|
|
WO2001014424A2
(en)
|
1999-08-24 |
2001-03-01 |
Medarex, Inc. |
Human ctla-4 antibodies and their uses
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
WO2001054732A1
(en)
|
2000-01-27 |
2001-08-02 |
Genetics Institute, Llc. |
Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
|
|
US6316029B1
(en)
|
2000-05-18 |
2001-11-13 |
Flak Pharma International, Ltd. |
Rapidly disintegrating solid oral dosage form
|
|
US6982251B2
(en)
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
|
US6814978B2
(en)
|
2000-12-29 |
2004-11-09 |
Mcneil-Ppc, Inc. |
Process for preparing a soft tablet
|
|
US6509040B1
(en)
|
2001-06-22 |
2003-01-21 |
R.P. Scherer Corporation |
Fast dispersing dosage forms essentially free of mammalian gelatin
|
|
AU2002334939A1
(en)
|
2001-10-12 |
2003-04-22 |
Eugene R. Cooper |
Compositions having a combination of particles for immediate release and for controlled release
|
|
EP1485296B1
(en)
|
2002-02-13 |
2011-07-20 |
Michael K. Weibel |
Drug dose - form and method of manufacture
|
|
DK1487856T3
(da)
|
2002-03-04 |
2010-10-18 |
Imclone Llc |
KDR-specifikke humane antistoffer og deres anvendelse
|
|
WO2004010947A2
(en)
|
2002-07-30 |
2004-02-05 |
Bristol-Myers Squibb Company |
Humanized antibodies against human 4-1bb
|
|
ES2393485T3
(es)
|
2003-07-02 |
2012-12-21 |
Innate Pharma |
Anticuerpos del receptor de NK pan-kir2dl y su uso en diagnóstico y terapia
|
|
CA2532547C
(en)
|
2003-07-24 |
2020-02-25 |
Innate Pharma |
Methods and compositions for increasing the efficiency of therapeutic antibodies using nk cell potentiating compounds
|
|
US7282217B1
(en)
|
2003-08-29 |
2007-10-16 |
Kv Pharmaceutical Company |
Rapidly disintegrable tablets
|
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
|
CA2601417C
(en)
|
2004-07-01 |
2018-10-30 |
Novo Nordisk A/S |
Human anti-kir antibodies
|
|
EA011725B1
(ru)
|
2004-08-26 |
2009-04-28 |
Пфайзер Инк. |
Пиразолзамещённые аминогетероарильные соединения в качестве ингибиторов протеинкиназы
|
|
EA013678B1
(ru)
|
2004-08-26 |
2010-06-30 |
Пфайзер Инк. |
Энантиомерно чистые аминогетероарильные соединения в качестве ингибиторов протеинкиназы
|
|
WO2006055809A2
(en)
|
2004-11-18 |
2006-05-26 |
Imclone Systems Incorporated |
Antibodies against vascular endothelial growth factor receptor-1
|
|
JP5855326B2
(ja)
|
2005-01-06 |
2016-02-09 |
ノヴォ ノルディスク アー／エス |
抗ｋｉｒ組み合わせ治療および方法
|
|
EP1836225B1
(en)
|
2005-01-06 |
2011-11-02 |
Novo Nordisk A/S |
Kir-binding agents and methods of use thereof
|
|
DK1866339T3
(da)
|
2005-03-25 |
2013-09-02 |
Gitr Inc |
GTR-bindende molekyler og anvendelser heraf
|
|
DK2161336T4
(en)
|
2005-05-09 |
2017-04-24 |
Ono Pharmaceutical Co |
Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
|
|
RS54271B1
(sr)
|
2005-07-01 |
2016-02-29 |
E. R. Squibb & Sons, L.L.C. |
Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1)
|
|
EP1744020A1
(de)
|
2005-07-14 |
2007-01-17 |
Siemens Aktiengesellschaft |
Verfahren zum Starten einer Dampfturbinenanlage
|
|
EP2322557B1
(en)
|
2005-10-14 |
2017-08-30 |
Innate Pharma |
Compositions and methods for treating proliferative disorders
|
|
US8158152B2
(en)
|
2005-11-18 |
2012-04-17 |
Scidose Llc |
Lyophilization process and products obtained thereby
|
|
RU2387650C2
(ru)
|
2005-12-05 |
2010-04-27 |
Пфайзер Продактс Инк. |
Полиморфы с-met/hgfr ингибитора
|
|
SI1959955T1
(sl)
|
2005-12-05 |
2011-02-28 |
Pfizer Prod Inc |
Postopek zdravljenja abnormalne celične rasti
|
|
US8048449B2
(en)
|
2005-12-27 |
2011-11-01 |
Jubilant Organosys Ltd. |
Mouth dissolving pharmaceutical composition and process for preparing the same
|
|
WO2007113648A2
(en)
|
2006-04-05 |
2007-10-11 |
Pfizer Products Inc. |
Ctla4 antibody combination therapy
|
|
DK2529622T3
(en)
|
2006-09-22 |
2018-05-07 |
Pharmacyclics Llc |
INHIBITORS OF BRUTON-TYROSINKINASE
|
|
EP2109460B1
(en)
|
2007-01-11 |
2016-05-18 |
Novo Nordisk A/S |
Anti-kir antibodies, formulations, and uses thereof
|
|
JP2008278814A
(ja)
|
2007-05-11 |
2008-11-20 |
Igaku Seibutsugaku Kenkyusho:Kk |
アゴニスティック抗ヒトｇｉｔｒ抗体による免疫制御の解除とその応用
|
|
NZ582150A
(en)
|
2007-06-18 |
2012-08-31 |
Msd Oss Bv |
Antibodies to human programmed death receptor pd-1
|
|
WO2009002084A2
(en)
|
2007-06-27 |
2008-12-31 |
Hanmi Pharm. Co., Ltd. |
Method for preparing rapidly disintegrating formulation for oral administration and apparatus for preparing and packing the same
|
|
ES2776406T3
(es)
|
2007-07-12 |
2020-07-30 |
Gitr Inc |
Terapias de combinación que emplean moléculas de enlazamiento a GITR
|
|
HRP20150074T1
(hr)
|
2007-10-01 |
2015-03-13 |
Bristol-Myers Squibb Company |
Humana antitijela koja se vežu za mezotelin i njihove uporabe
|
|
CN101918030B
(zh)
|
2007-11-09 |
2015-10-14 |
派瑞格恩医药公司 |
抗vegf抗体的组合物和方法
|
|
TW200938224A
(en)
|
2007-11-30 |
2009-09-16 |
Medarex Inc |
Anti-B7H4 monoclonal antibody-drug conjugate and methods of use
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
US8221480B2
(en)
|
2008-10-31 |
2012-07-17 |
The Invention Science Fund I, Llc |
Compositions and methods for biological remodeling with frozen particle compositions
|
|
US8256233B2
(en)
|
2008-10-31 |
2012-09-04 |
The Invention Science Fund I, Llc |
Systems, devices, and methods for making or administering frozen particles
|
|
US8709411B2
(en)
|
2008-12-05 |
2014-04-29 |
Novo Nordisk A/S |
Combination therapy to enhance NK cell mediated cytotoxicity
|
|
HRP20170908T1
(hr)
|
2008-12-09 |
2017-09-22 |
F. Hoffmann - La Roche Ag |
Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
|
|
US8709424B2
(en)
|
2009-09-03 |
2014-04-29 |
Merck Sharp & Dohme Corp. |
Anti-GITR antibodies
|
|
US8313768B2
(en)
|
2009-09-24 |
2012-11-20 |
Mcneil-Ppc, Inc. |
Manufacture of tablet having immediate release region and sustained release region
|
|
FR2957077B1
(fr)
*
|
2010-03-02 |
2012-04-13 |
Univ Dauvergne Clermont I |
Utilisation du riluzole pour traiter ou prevenir les effets indesirables d'agents anti-cancereux
|
|
ES2608475T3
(es)
|
2010-04-13 |
2017-04-11 |
Celldex Therapeutics, Inc. |
Anticuerpos que se unen a cd27 humana y usos de los mismos
|
|
TWI500617B
(zh)
|
2010-05-31 |
2015-09-21 |
Ono Pharmaceutical Co |
Purine ketone derivatives
|
|
RU2013121744A
(ru)
*
|
2010-10-13 |
2014-11-20 |
Мустафа Билгин Али ДЖАМГОЗ |
Лечение рака/ингибирование метастазирования
|
|
CN106963947A
(zh)
|
2010-11-22 |
2017-07-21 |
伊纳特医药股份有限公司 |
Nk细胞调节治疗和用于治疗血液恶性疾病的方法
|
|
MX360254B
(es)
|
2011-03-10 |
2018-10-26 |
Pfizer |
Combinacion de terapias inmunomoduladoras local y sistemica para tratamiento mejorado del cancer.
|
|
AU2012260601B2
(en)
|
2011-05-25 |
2018-02-01 |
Innate Pharma, S.A. |
Anti-KIR antibodies for the treatment of inflammatory disorders
|
|
MX2014001354A
(es)
|
2011-08-02 |
2014-10-14 |
Pfizer |
Crizotinib para uso en el tratamiento de cancer.
|
|
US20130108641A1
(en)
|
2011-09-14 |
2013-05-02 |
Sanofi |
Anti-gitr antibodies
|
|
US9041556B2
(en)
|
2011-10-20 |
2015-05-26 |
Apple Inc. |
Method for locating a vehicle
|
|
BR112014011144A2
(pt)
|
2011-11-09 |
2017-05-16 |
Bristol Myers Squibb Co |
tratamento de malignidades hematológicas com um anticorpo anti-cxcr4
|
|
US10864271B2
(en)
*
|
2012-02-15 |
2020-12-15 |
Rutgers, The State University Of New Jersey |
Combination therapy using riluzole to enhance tumor sensitivity to ionizing radiation
|
|
US9725427B2
(en)
|
2012-03-16 |
2017-08-08 |
Biohaven Pharmaceutical Holding Company Limited |
Prodrugs of riluzole and their method of use
|
|
CA2873402C
(en)
|
2012-05-15 |
2023-10-24 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
|
KR101566539B1
(ko)
|
2012-06-08 |
2015-11-05 |
국립암센터 |
신규한 Ｔｈ2 세포 전환용 에피토프 및 이의 용도
|
|
WO2013192610A2
(en)
|
2012-06-23 |
2013-12-27 |
Fox Chase Chemical Diversity Center, Inc. |
Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
SG10201702421TA
(en)
|
2012-10-02 |
2017-05-30 |
Bristol Myers Squibb Co |
Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer
|
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
PL3508502T3
(pl)
|
2013-09-20 |
2023-07-17 |
Bristol-Myers Squibb Company |
Kombinacja przeciwciał anty-lag-3 i przeciwciał anty-pd-1 w leczeniu raka
|
|
CN103536594A
(zh)
*
|
2013-10-21 |
2014-01-29 |
江苏亚虹医药科技有限公司 |
G蛋白偶联受体拮抗剂在用于制备治疗谷氨酸受体高表达肿瘤药物中的用途
|
|
AU2014339816B2
(en)
|
2013-10-25 |
2020-05-28 |
Pharmacyclics Llc |
Treatment using Bruton's tyrosine kinase inhibitors and immunotherapy
|
|
PL3148579T3
(pl)
|
2014-05-28 |
2021-07-19 |
Agenus Inc. |
Przeciwciała anty-gitr i sposoby ich zastosowania
|
|
KR102360693B1
(ko)
|
2014-07-11 |
2022-02-08 |
벤타나 메디컬 시스템즈, 인코포레이티드 |
항-pd-l1 항체 및 이의 진단 용도
|
|
CN106794246B
(zh)
*
|
2014-08-08 |
2021-10-15 |
OncoQuest制药有限公司 |
肿瘤抗原特异性抗体和tlr3刺激以增强检查点干扰癌症疗法的性能
|
|
US20160073759A1
(en)
*
|
2014-09-15 |
2016-03-17 |
Beauty Solutions Agency Inc. |
Nail covering
|
|
JP7305300B2
(ja)
*
|
2014-11-05 |
2023-07-10 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
併用免疫療法
|
|
US10235906B2
(en)
*
|
2014-11-18 |
2019-03-19 |
Maximum Fidelity Surgical Simulations, LLC |
Post mortem reconstitution of circulation
|
|
US20160140879A1
(en)
*
|
2014-11-19 |
2016-05-19 |
David Hananel |
Anatomically correct movement or deformation of simulated bodily structures
|
|
US11911369B2
(en)
*
|
2015-03-03 |
2024-02-27 |
Biohaven Therapeutics Ltd. |
Prodrugs of riluzole and their method of use
|
|
CA2978158C
(en)
|
2015-03-03 |
2022-04-12 |
Biohaven Pharmaceutical Holding Company Ltd. |
Riluzole prodrugs and their use
|
|
KR102740444B1
(ko)
|
2015-04-17 |
2024-12-10 |
브리스톨-마이어스 스큅 컴퍼니 |
항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물
|
|
ES2900482T3
(es)
|
2015-10-01 |
2022-03-17 |
Gilead Sciences Inc |
Combinación de un inhibidor de Btk y un inhibidor de punto de control para el tratamiento del cáncer
|
|
CN115350263A
(zh)
|
2016-05-20 |
2022-11-18 |
拜尔哈文制药股份有限公司 |
谷氨酸调节剂与免疫疗法用以治疗癌症的用途
|